Ohr Pharmaceutical Inc.

NASDAQ: OHRPHealthcare / Biotechnology / USA
5.39+1.25+30.19%Vol 1 581 9001Y Perf 28.33%
Jul 12th, 2019 18:55
BID0.0000 ASK0.0000
Open4.10 Previous Close4.14
Pre-Market- After-Trading-
 - -%  - -%
Target Price
0.40 
Analyst Rating
— 0.00
Potencial %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)15 
Earnings Rating
Neutral
Price Range Ratio 52wk %
80.98 
Earnings Date
13th Aug 2019

Today's Price Range

3.985.75

52wk Range

1.606.28

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.00%
1 Month
42.59%
3 Months
137.44%
6 Months
107.31%
1 Year
28.33%
3 Years
-89.31%
5 Years
-96.78%
10 Years
-

Name / TickerPriceChg.Chg.%
OHRP5.391.250030.19
AAPL202.59-3.0700-1.49
GOOG1 130.10-16.2300-1.42
MSFT136.620.20000.15
XOM74.990.15000.20
WFC46.030.21000.46
JNJ130.31-1.7600-1.33
FB198.36-2.4200-1.21
GE10.04-0.0200-0.20
JPM113.54-1.1300-0.99
Earnings HistoryEstimateReportedSurprise %
Q02 2018--0.05-
Q01 2018--0.07-
Q04 2017-0.08-0.080.00
Q03 2017-0.25-0.0772.00
Q02 2017-0.30-0.2130.00
Q01 2017-0.19-0.21-10.53
Q04 2016-0.24-0.2112.50
Q03 2016-0.23-0.24-4.35
Earnings Per EndEstimateRevision %Trend
12/2017 QR-0.0795.48Positive
3/2018 QR-0.07--
9/2018 FY-0.52--
9/2019 FY-0.810.00-
Next Report Date13th Aug 2019
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1 581 900
Shares Outstanding (in ths.)2 829
Trades Count4 455
Dollar Volume7 231 480
Avg. Volume180 228
Avg. Weekly Volume727 580
Avg. Monthly Volume243 855
Avg. Quarterly Volume137 098
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Hold
3.00

Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc is a US-based pharmaceutical company which focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The lead product of the company is topical Squalamine is a novel therapeutic product which provides non-invasive therapy to improve visual outcomes. Its product pipeline includes SQUALAMINE LACTATE OPHTHALMIC SOLUTION 0.2%, SKS sustained release ocular drug delivery platform technology, Animal Model for Dry-AMD, and Non-Ophthalmology Assets.

CEO: Jason Slakter

Teplephone: +1 212 682-8452

Address: 800 Third Avenue, 11th Floor, New York 10022, NY, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

54%46%

Bearish Bullish

64%36%

News